ADVANCED PHARMACOLOGY - II

(MPL 201T)

Scope
.?< JL9A<:K @J ;<J@>E<; KF JKI<E>K?<E K?< 98J@: BEFNC<;>< @E K?< =@<C; F=
G?8ID8:FCF>P 8E; KF @DG8IK I<:<EK 8;M8E:<J @E K?< ;IL>J LJ<; =FI K?< KI<8KD<EK
F= M8I@FLJ ;@J<8J<J #E 8;;@K@FE
K?< JL9A<:K ?<CGJ K?< JKL;<EK KF LE;<IJK8E; K?<
:FE:<GKJ F= ;IL> 8:K@FE 8E; D<:?8E@JD @EMFCM<;

Objectives
/GFE :FDGC<K@FE F= K?< :FLIJ< K?< JKL;<EK J?8CC 9< 89C< KF
• OGC8@E K?< D<:?8E@JD F= ;IL> 8:K@FEJ 8K :<CCLC8I 8E; DFC<:LC8I C<M<C
• @J:LJJ K?< *8K?FG?PJ@FCF>P 8E; G?8ID8:FK?<I8GP F= :<IK8@E ;@J<8J<J
• /E;<IJK8E; K?< 8;M<IJ< <==<:KJ
:FEKI8@E;@:8K@FEJ 8E; :C@E@:8C LJ<J F=
;IL>J LJ<; @E KI<8KD<EK F= ;@J<8J<J

THEORY 60 Hrs
 Endocrine Pharmacology 
'FC<:LC8I 8E; :<CCLC8I D<:?8E@JD

F= 8:K@FE F= ?FIDFE<J JL:? 8J "IJ
>IFNK? ?FIDFE<

GIFC8:K@E
K?PIF@;
@EJLC@E 8E; J<O ?FIDFE<J
EK@K?PIF@; ;IL>J
)I8C ?PGF>CP:<D@: 8><EKJ
)I8C
:FEKI8:<GK@M<J
FIK@:FJK<IF@;J
IL>J 8==<:K@E>
:8C:@LD I<>LC8K@FE
 Chemotherapy 
<CCLC8I 8E; DFC<:LC8I

D<:?8E@JD F= 8:K@FEJ 8E; I<J@JK8E:< F= "IJ
8EK@D@:IF9@8C 8><EKJ
JL:? 8J TC8:K8DJ
8D@EF>CP:FJ@;<J
HL@EFCFE<J
'8:IFC@;<
8EK@9@FK@:J EK@=LE>8C
8EK@M@I8C
8E; 8EK@. ;IL>J

 Chemotherapy 
IL>J LJ<; @E *IFKFQF8C #E=<:K@FEJ "IJ
IL>J LJ<; @E K?< KI<8KD<EK F= "<CD@EK?@8J@J
?<DFK?<I8GP F= :8E:<I
Immunopharmacology
<CCLC8I 8E; 9@F:?<D@:8C D<;@8KFIJ F= @E=C8DD8K@FE 8E; @DDLE<
I<JGFEJ< CC<I>@: FI
?PG<IJ<EJ@K@M@KP I<8:K@FEJ *?8ID8:FK?<I8GP F= 8JK?D8 8E;
)*
#DDLEFJLGGI<JJ8EKJ 8E; #DDLEFJK@DLC8EKJ


 GIT Pharmacology 
EK@LC:<I ;IL>J
*IFB@E<K@:J
8EK@<D<K@:J
8EK@;@8II?<8CJ 8E; "IJ
;IL>J =FI :FEJK@G8K@FE
8E; @II@K89C< 9FN<C JPE;IFD<
Chronopharmacology
@FCF>@:8C 8E; :@I:8;@8E I?PK?DJ
8GGC@:8K@FEJ F= :?IFEFK?<I8GP @E
M8I@FLJ ;@J<8J<J C@B<
:8I;@FM8J:LC8I ;@J<8J<
;@89<K<J
8JK?D8 8E; G<GK@: LC:<I

 Free radicals Pharmacology 

!<E<I8K@FE F= =I<< I8;@:8CJ
IFC< F= =I<< I8;@:8CJ @E <K@FG8K?FCF>P F= "IJ
M8I@FLJ ;@J<8J<J
JL:? 8J ;@89<K<J
E<LIF;<><E<I8K@M< ;@J<8J<J 8E; :8E:<I
*IFK<:K@M< 8:K@M@KP F= :<IK8@E @DGFIK8EK 8EK@FO@;8EK
Recent Advances in Treatment:
CQ?<@D<I`J ;@J<8J<
*8IB@EJFE`J ;@J<8J<
8E:<I
@89<K<J
D<CC@KLJ

REFERENCES
 .?< *?8ID8:FCF>@:8C 98J@J F= K?<I8G<LK@:J !FF;D8E 8E; !@CC D8E_J
 *I@E:@GC<J F= *?8ID8:FCF>P .?< *8K?FG?PJ@FCF>@: 98J@J F= ;IL> K?<I8GP 9P
8M@;  !FC8E <K 8C
 8J@: 8E; C@E@:8C *?8ID8:FCF>P 9P ! %8KQLE>
 *?8ID8:FCF>P 9P "* ,8E> 8E; '' 8C<
 "8E; 9FFB F= C@E@:8C *?8ID8:FB@E<K@:J 9P !@98C;@ 8E; *I<J:FKK
 .<OK 9FFB F= .?<I8G<LK@:J
;IL> 8E; ;@J<8J< D8E8><D<EK 9P  .
"<I=@E;8C 8E; !FLIC<P
 GGC@<; 9@FG?8ID8:<LK@:J 8E; *?8ID8:FB@E<K@:J 9P &<FE -?8I><C 8E;
E;I<N 3L
 "8E;9FFB F= JJ<EK@8C *?8ID8:FB@E<K@:J
*?8ID8:F;PE8D@:J 8E; IL>
'<K89FC@JD =FI
#E;LJKI@8C -:@<EK@JKJ
 ,F99@EJ  FIK8E *8K?FCF>@: 8J@J F= @J<8J<
K? ; ,F99@EJ
*8K?FCF>P
  FDGC<K< .<OK9FFB F= '<;@:8C *?8ID8:FCF>P 9P I -% -I@M8JK8M8
GL9C@J?<; 9P * M@:?8C *L9C@J?@E> FDG8EP
 %.I@G8K?@ JJ<EK@8CJ F= '<;@:8C *?8ID8:FCF>P
 *I@E:@GC<J F= *?8ID8:FCF>P .?< *8K?FG?PJ@FCF>@: 98J@J F= ;IL> .?<I8GP
9P 8M@;  !FC8E
ID<E "
.8J?A@8E $I
?I@E $
IDJKIFE>
GI@C 1

IDJKIFE>
1FCK<IJ
%CLN<I&@GG@E:FKK 1@CC@8DJ  1@CB@EJ *L9C@J?<IJ


 PHARMACOLOGICAL AND TOXICOLOGICAL SCREENING
METHODS-II
(MPL 202T)

Scope:
.?@J JL9A<:K @DG8IKJ BEFNC<;>< FE K?< GI<:C@E@:8C J8=<KP 8E; KFO@:FCF>@:8C
<M8CL8K@FE F= ;IL>  E<N :?<D@:8C <EK@KP .?@J BEFNC<;>< N@CC D8B< K?< JKL;<EK
:FDG<K<EK @E I<>LC8KFIP KFO@:FCF>@:8C <M8CL8K@FE

Objectives:
/GFE :FDGC<K@FE F= K?< :FLIJ<
K?< JKL;<EK J?8CC 9< 89C< KF

• OGC8@E K?< M8I@FLJ KPG<J F= KFO@:@KP JKL;@<J

• GGI<:@8K< K?< @DGFIK8E:< F= <K?@:8C 8E; I<>LC8KFIP I<HL@I<D<EKJ =FI
KFO@:@KP JKL;@<J
• <DFEJKI8K< K?< GI8:K@:8C JB@CCJ I<HL@I<; KF :FE;L:K K?< GI<:C@E@:8C
KFO@:@KP JKL;@<J

THEORY 60 Hrs
 8J@: ;<=@E@K@FE 8E; KPG<J F= KFO@:FCF>P ><E<I8C
D<:?8E@JK@:

I<>LC8KFIP 8E; ;<J:I@GK@M< "IJ
,<>LC8KFIP >L@;<C@E<J =FI :FE;L:K@E> KFO@:@KP JKL;@<J )
#"

* 8E; -:?<;LC< 3

) GI@E:@GC<J F= !FF; C89FI8KFIP GI8:K@:< !&*
"@JKFIP
:FE:<GK 8E; @KJ @DGFIK8E:< @E
;IL> ;<M<CFGD<EK

 :LK<
JL98:LK< 8E; :?IFE@: FI8C
;<ID8C 8E; @E?8C8K@FE8C 
JKL;@<J 8J G<I ) >L@;<C@E<J "IJ
:LK< <P< @II@K8K@FE
JB@E J<EJ@K@Q8K@FE
;<ID8C @II@K8K@FE  ;<ID8C
KFO@:@KP JKL;@<J
.<JK @K<D :?8I8:K<I@Q8K@FE @DGFIK8E:< 8E; D<K?F;J @E I<>LC8KFIP
KFO@:FCF>P JKL;@<J
 ,<GIF;L:K@M< KFO@:FCF>P JKL;@<J
'8C< I<GIF;L:K@M< KFO@:@KP 
JKL;@<J
=<D8C< I<GIF;L:K@M< JKL;@<J J<>D<EK # 8E; J<>D<EK ###
"IJ
K<I8KF><E<:@KP JKL;@<J J<>D<EK ##
!<EFKFO@:@KP JKL;@<J D<J .<JK, in vitro 8E; in vivo '@:IFEL:C<LJ
8E; ?IFDFJFD8C 89<II8K@FEJ JKL;@<J
In vivo :8I:@EF><E@:@KP JKL;@<J
 #( <E89C@E> JKL;@<J #( JKL;@<J <=@E@K@FE F= #(
@DGFIK8E:< 
F= #(
@E;LJKIP G<IJG<:K@M<
C@JK F= JKL;@<J E<<;<; =FI #( "IJ
JL9D@JJ@FE


 -8=<KP G?8ID8:FCF>P JKL;@<J FI@>@E
:FE:<GKJ 8E; @DGFIK8E:< F=
J8=<KP G?8ID8:FCF>P
.@<I 0-
(- 8E; I<JG@I8KFIP J8=<KP G?8ID8:FCF>P
",!
8JJ8P .@<I !#
I<E8C 8E; FK?<I JKL;@<J

 .FO@:FB@E<K@:J .FO@:FB@E<K@: <M8CL8K@FE @E GI<:C@E@:8C JKL;@<J


J8KLI8K@FE B@E<K@:J #DGFIK8E:< 8E; 8GGC@:8K@FEJ F= KFO@:FB@E<K@: "IJ
JKL;@<J
CK<IE8K@M< D<K?F;J KF 8E@D8C KFO@:@KP K<JK@E>

REFERENCES
 "8E; 9FFB FE !&*
+L8C@KP GI8:K@:<J =FI I<>LC8K<; EFE:C@E@:8C I<J<8I:?
8E; ;<M<CFGD<EK ?KKG NNNN?F@EK K;I GL9C@:8K@FEJ ;F:LD<EKJ >CG
?8E;9FFBG;=
 -:?<;LC< 3 !L@;<C@E< ;IL>J 8E; :FJD<K@:J J<:FE; 8D<E;D<EK ILC<J


D@E@JKIP F= ?<8CK? 8E; =8D@CP N<C=8I< ;<G8IKD<EK F= ?<8CK? (<N
<C?@
 IL>J =IFD ;@J:FM<IP KF 8GGIFM8C 9P ,@:B (!
 E@D8C 'F;<CJ @E .FO@:FCF>P
I; ;@K@FE
&FN<I 8E; IP8E
 ) K<JK >L@;<C@E<J
 *I@E:@GC<J F= KFO@:FCF>P 9P %8I<E  -K@E<
.?FD8J ' IFNE
 !L@;8E:< =FI #E;LJKIP ', (FE:C@E@:8C -8=<KP -KL;@<J =FI K?< FE;L:K
F= "LD8E C@E@:8C .I@8CJ 8E; '8IB<K@E> LK?FI@Q8K@FE =FI *?8ID8:<LK@:8CJ
?KKG NNN=;8>FM ;FNECF8;J ;IL>J >L@;8E:<:FDGC@8E:<I<>LC8KFIP@E=FID
8K@FE >L@;8E:<J L:DG;=


 PRINCIPLES OF DRUG DISCOVERY
(MPL 203T)

Scope:
.?< JL9A<:K @DG8IKJ 98J@: BEFNC<;>< F= ;IL> ;@J:FM<IP GIF:<JJ .?@J
@E=FID8K@FE
N@CC D8B< K?< JKL;<EK :FDG<K<EK @E
;IL> ;@J:FM<IP GIF:<JJ

Objectives:
/GFE :FDGC<K@FE F= K?< :FLIJ<
K?< JKL;<EK J?8CC 9< 89C< KF

• OGC8@E K?< M8I@FLJ JK8><J F= ;IL> ;@J:FM<IP

• GGI<:@8K< K?< @DGFIK8E:< F= K?< IFC< F= ><EFD@:J
GIFK<FD@:J 8E;
9@F@E=FID8K@:J @E ;IL> ;@J:FM<IP
• OGC8@E M8I@FLJ K8I><KJ =FI ;IL> ;@J:FM<IP
• OGC8@E M8I@FLJ C<8; J<<B@E> D<K?F; 8E; C<8; FGK@D@Q8K@FE
• GGI<:@8K< K?< @DGFIK8E:< F= K?< IFC< F= :FDGLK<I 8@;<; ;IL> ;<J@>E @E
;IL> ;@J:FM<IP

THEORY 60 Hrs
 E FM<IM@<N F= DF;<IE

;IL> ;@J:FM<IP GIF:<JJ .8I><K 
@;<EK@=@:8K@FE
K8I><K M8C@;8K@FE
C<8; @;<EK@=@:8K@FE 8E; C<8; "IJ
)GK@D@Q8K@FE :FEFD@:J F= ;IL> ;@J:FM<IP
.8I><K @J:FM<IP 8E; M8C@;8K@FE,FC< F= !<EFD@:J
*IFK<FD@:J
8E; @F@E=FID8K@:J ,FC< F= (L:C<@: 8:@; D@:IF8II8PJ
*IFK<@E
D@:IF8II8PJ
EK@J<EJ< K<:?EFCF>@<J
J@,(J

8EK@J<EJ<
FC@>FEL:C<FK@;<J
4@E: eE><I GIFK<@EJ ,FC< F= KI8EJ><E@: 8E@D8CJ
@E K8I><K M8C@;8K@FE
 &<8; #;<EK@=@:8K@FE :FD9@E8KFI@8C :?<D@JKIP  ?@>? K?IFL>?GLK 
J:I<<E@E>
@E J@C@:F C<8; ;@J:FM<IP K<:?E@HL<J
JJ8P ;<M<CFGD<EK "IJ
=FI ?@K @;<EK@=@:8K@FE
*IFK<@E JKIL:KLI<
&<M<CJ F= GIFK<@E JKIL:KLI<
FD8@EJ
DFK@=J
8E; =FC;J @E GIFK<@E
JKIL:KLI< FDGLK8K@FE8C GI<;@:K@FE F= GIFK<@E JKIL:KLI< .?I<8;@E>
8E; ?FDFCF>P DF;<C@E> D<K?F;J GGC@:8K@FE F= (', 8E; 2I8P
:IPJK8CCF>I8G?P @E GIFK<@E JKIL:KLI< GI<;@:K@FE
 ,8K@FE8C IL> <J@>E 
.I8;@K@FE8C MJ I8K@FE8C ;IL> ;<J@>E
'<K?F;J =FCCFN<; @E KI8;@K@FE8C "IJ
;IL> ;<J@>E
"@>? K?IFL>?GLK J:I<<E@E>
FE:<GKJ F= ,8K@FE8C
IL> <J@>E
,8K@FE8C IL> <J@>E '<K?F;J -KIL:KLI< 8E;
*?8ID8:FG?FI< 98J<; 8GGIF8:?<J


 0@IKL8C -:I<<E@E> K<:?E@HL<J IL> C@B<E<JJ J:I<<E@E>
FE:<GK
F= G?8ID8:FG?FI< D8GG@E> 8E; G?8ID8:FG?FI< 98J<;
-:I<<E@E>

 'FC<:LC8I ;F:B@E> ,@>@; ;F:B@E>

=C<O@9C< ;F:B@E>
D8EL8C 
;F:B@E> F:B@E> 98J<; J:I<<E@E> < EFMF ;IL> ;<J@>E "IJ
+L8EK@K8K@M< 8E8CPJ@J F= -KIL:KLI< :K@M@KP ,<C8K@FEJ?@G
"@JKFIP 8E; ;<M<CFGD<EK F= +-,
-, M<IJLJ +-,

*?PJ@:F:?<D@:8C G8I8D<K<IJ
"8EJ:? 8E8CPJ@J
<< 1@CJFE
8E8CPJ@J 8E; I<C8K@FEJ?@G 9<KN<<E K?<D

 +-, -K8K@JK@:8C D<K?F;J \ I<>I<JJ@FE 8E8CPJ@J

G8IK@8C C<8JK 
JHL8I< 8E8CPJ@J *&- 8E; FK?<I DLCK@M8I@8K< JK8K@JK@:8C D<K?F;J "IJ
+-, 8GGIF8:?<J C@B< )'  8E; )'-#
*IF;IL> ;<J@>E8J@: :FE:<GK
*IF;IL>J KF @DGIFM< G8K@<EK
8::<GK89@C@KP
IL> JFCL9@C@KP
IL> 89JFIGK@FE 8E; ;@JKI@9LK@FE
J@K<
JG<:@=@: ;IL> ;<C@M<IP 8E; JLJK8@E<; ;IL> 8:K@FE ,8K@FE8C< F=
GIF;IL> ;<J@>E 8E; GI8:K@:8C :FEJ@;<I8K@FE F= GIF;IL> ;<J@>E

REFERENCES
 'FLC;P-@FL; .8I><K @J:FM<IP 8E; 08C@;8K@FE ,<M@<NJ 8E; *IFKF:FCJ
0FCLD<  D<I>@E> 'FC<:LC8I .8I><KJ8E; .I<8KD<EK )GK@FEJ 
"LD8E8 *I<JJ #E:
 8IIPC &<UE -:FKK '8IB<C#E -@C@:F .<:?EFCF>@<J @E IL> .8I><K
#;<EK@=@:8K@FE 8E; 08C@;8K@FE  9P .8PCFI 8E; I8E:@J !IFLG
&&
 $F?8EE8 % @-K<=8EF @J<8J< !<E< #;<EK@=@:8K@FE '<K?F;J 8E;
*IFKF:FCJ -GI@E><I (<N 3FIB FI;I<:?K "<@;<C9<I> &FE;FE
 "L>F %L9@EP +-, "8EJ:? E8CPJ@J 8E; ,<C8K<; GGIF8:?<J '<K?F;J
8E; *I@E:@GC<J @E '<;@:@E8C ?<D@JKIP *L9C@J?<I 1@C<P0"
 %C8LJ !L9<IE8KFI
"8EJ$F8:?@D W?D -KIL:KLI<8J<; &@>8E; <J@>E
'<K?F;J 8E; *I@E:@GC<J @E '<;@:@E8C ?<D@JKIP *L9C@J?<I 1@C<P0"
 99P &  *8II@CC '  ,8D@ ,<;;P ,8K@FE8C IL> <J@>E (FM<C
'<K?F;FCF>P 8E; *I8:K@:8C GGC@:8K@FEJ - -PDGFJ@LD -<I@<J
D<I@:8E ?<D@:8C -F:@<KP 18J?@E>KFE


 $ ,@:B .LIE<I (<N ;IL> ;<M<CFGD<EK ;<J@>E
D<K?F;FCF>P 8E;
8E8CPJ@J
$F?E 1@C<P  -FEJ
#E:
(<N $<IJ<P


 CLINICAL RESEARCH AND PHARMACOVIGILANCE
(MPL 204T)

Scope:
.?@J JL9A<:K N@CC

GIFM@;< 8 M8CL< 8;;@K@FE 8E; :LII<EK I<HL@I<D<EK =FI K?<
JKL;<EKJ @E :C@E@:8C I<J<8I:? 8E; G?8ID8:FM@>@C8E:< #K N@CC K<8:? K?< JKL;<EKJ FE
:FE:<GKL8C@Q@E>
;<J@>E@E>
:FE;L:K@E>
D8E8>@E> 8E; I<GFIK@E> F= :C@E@:8C KI@8CJ
.?@J JL9A<:K 8CJF =F:LJ<J FE >CF98C J:<E8I@F F= *?8ID8:FM@>@C8E:< @E ;@==<I<EK
D<K?F;J K?8K :8E 9< LJ<; KF ><E<I8K< J8=<KP ;8K8 #K N@CC K<8:? K?< JKL;<EKJ @E
;<M<CFG@E> ;IL> J8=<KP ;8K8 @E *I<:C@E@:8C
C@E@:8C G?8J<J F= IL> ;<M<CFGD<EK
8E; GFJK D8IB<K JLIM<@CC8E:<

Objectives:
/GFE :FDGC<K@FE F= K?< :FLIJ<
K?< JKL;<EK J?8CC 9< 89C< KF

• OGC8@E K?< I<>LC8KFIP I<HL@I<D<EKJ =FI :FE;L:K@E> :C@E@:8C KI@8C

• <DFEJKI8K< K?< KPG<J F= :C@E@:8C KI@8C ;<J@>EJ
• OGC8@E K?< I<JGFEJ@9@C@K@<J F= B<P GC8P<IJ @EMFCM<; @E :C@E@:8C KI@8CJ
• O<:LK< J8=<KP DFE@KFI@E>
I<GFIK@E> 8E; :CFJ<FLK 8:K@M@K@<J
• OGC8@E K?< GI@E:@GC<J F= *?8ID8:FM@>@C8E:<
• <K<:K E<N
8;M<IJ< ;IL> I<8:K@FEJ 8E; K?<@I 8JJ<JJD<EK
• *<I=FID K?< 8;M<IJ< ;IL> I<8:K@FE I<GFIK@E> JPJK<DJ 8E;
:FDDLE@:8K@FE @E *?8ID8:FM@>@C8E:<

THEORY 60 Hrs
 Regulatory Perspectives of Clinical Trials: 
)I@>@E 8E; *I@E:@GC<J F= #EK<IE8K@FE8C FE=<I<E:< FE "IJ
"8IDFE@Q8K@FE  !FF; C@E@:8C *I8:K@:< #"!* >L@;<C@E<J
Ethical Committee: #EJK@KLK@FE8C ,<M@<N F8I;
K?@:8C
!L@;<C@E<J =FI @FD<;@:8C ,<J<8I:? 8E; "LD8E *8IK@:@G8EK
-:?<;LC< 3
#',
Informed Consent Process: -KIL:KLI< 8E; :FEK<EK F= 8E
#E=FID<; FEJ<EK *IF:<JJ K?@:8C GI@E:@GC<J >FM<IE@E> @E=FID<;
:FEJ<EK GIF:<JJ
 Clinical Trials: .PG<J 8E; <J@>E 
OG<I@D<EK8C -KL;P ,. 8E; (FE ,.
"IJ
)9J<IM8K@FE -KL;P F?FIK
8J< FEKIFC
IFJJ J<:K@FE8C
Clinical Trial Study Team
,FC<J 8E; I<JGFEJ@9@C@K@<J F= C@E@:8C .I@8C *<IJFEE<C #EM<JK@>8KFI

-KL;P FFI;@E8KFI
-GFEJFI
FEKI8:K ,<J<8I:? )I>8E@Q8K@FE 8E;
@KJ D8E8><D<EK


 Clinical Trial Documentation- !L@;<C@E<J KF K?< GI<G8I8K@FE F= 
;F:LD<EKJ
*I<G8I8K@FE F= GIFKF:FC
#EM<JK@>8KFI IF:?LI<
8J< "IJ
,<GFIK FIDJ
C@E@:8C -KL;P ,<GFIK C@E@:8C .I@8C 'FE@KFI@E>
-8=<KP 'FE@KFI@E> @E .
Adverse Drug Reactions: <=@E@K@FE 8E; KPG<J <K<:K@FE 8E;
I<GFIK@E> D<K?F;J -<M<I@KP 8E; J<I@FLJE<JJ
8JJ<JJD<EK*I<;@:K89@C@KP 8E; GI<M<EK89@C@KP 8JJ<JJD<EK

'8E8><D<EK F= 8;M<IJ< ;IL> I<8:K@FEJ .<ID@EFCF>@<J F= ,

 Basic aspects, terminologies and establishment of 

pharmacovigilance "IJ
"@JKFIP 8E; GIF>I<JJ F= G?8ID8:FM@>@C8E:<
-@>E@=@:8E:< F= J8=<KP
DFE@KFI@E>
*?8ID8:FM@>@C8E:< @E #E;@8 8E; @EK<IE8K@FE8C 8JG<:KJ

1") @EK<IE8K@FE8C ;IL> DFE@KFI@E>
GIF>I8DD<

1") 8E;
,<>LC8KFIP K<ID@EFCF>@<J F= ,
<M8CL8K@FE F= D<;@:8K@FE J8=<KP

JK89C@J?@E> G?8ID8:FM@>@C8E:< :<EKI<J @E "FJG@K8CJ

#E;LJKIP 8E;
(8K@FE8C GIF>I8DD<J I<C8K<; KF G?8ID8:FM@>@C8E:< ,FC<J 8E;
I<JGFEJ@9@C@K@<J @E *?8ID8:FM@>@C8E:<

 Methods, ADR reporting and tools used in 

Pharmacovigilance "IJ
#EK<IE8K@FE8C :C8JJ@=@:8K@FE F= ;@J<8J<J
#EK<IE8K@FE8C (FE
GIFGI@<K8IP E8D<J =FI

;IL>J
*8JJ@M< 8E; :K@M< JLIM<@CC8E:<

FDG8I8K@M< F9J<IM8K@FE8C JKL;@<J

.8I><K<; :C@E@:8C @EM<JK@>8K@FEJ
8E; 08::@E< J8=<KP JLIM<@CC8E:< -GFEK8E<FLJ I<GFIK@E> JPJK<D
8E; ,<GFIK@E> KF I<>LC8KFIP 8LK?FI@K@<J
!L@;<C@E<J =FI ,J
I<GFIK@E>
I>LJ
I@J ! *?8ID8:FM@>@C8E:<
0@>@ CFN
-K8K@JK@:8C
D<K?F;J =FI <M8CL8K@E> D<;@:8K@FE J8=<KP ;8K8

 Pharmacoepidemiology, pharmacoeconomics, safety 

pharmacology "IJ

REFERENCES
 <EKI8C IL>J -K8E;8I; FEKIFC )I>8E@Q8K@FE !FF; C@E@:8C *I8:K@:<J

!L@;<C@E<J =FI C@E@:8C .I@8CJ FE *?8ID8:<LK@:8C *IF;L:KJ @E #E;@8 (<N

<C?@ '@E@JKIP F= "<8CK?
 #EK<IE8K@FE8C FE=<I<E:< FE "8IDFE@Q8K@FE F= .<:?E@:8C I<HL@I<D<EKJ =FI
I<>@JKI8K@FE F= *?8ID8:<LK@:8CJ =FI ?LD8E LJ< #" "8IDFE@Q<; .I@G8IK@K<
!L@;<C@E< !L@;<C@E< =FI !FF; C@E@:8C *I8:K@:< '8P 


 K?@:8C !L@;<C@E<J =FI @FD<;@:8C ,<J<8I:? FE "LD8E -L9A<:KJ 
#E;@8E FLE:@C F= '<;@:8C ,<J<8I:?
(<N <C?@
 .<OK9FFB F= C@E@:8C .I@8CJ <;@K<; 9P 8M@; '8:?@E
-@DFE 8P 8E; -PCM8E
!I<<E
'8I:? 
$F?E 1@C<P 8E; -FEJ
 C@E@:8C 8K8 '8E8><D<EK <;@K<; 9P , % ,FE;<CJ
-  08IC<P

1<99J
-<:FE; ;@K@FE
$8E 
1@C<P *L9C@:8K@FEJ
 "8E;9FFB F= :C@E@:8C ,<J<8I:? $LC@8 &CFP; 8E; EE ,8M<E ; ?LI:?@CC
&@M@E>JKFE<
 *I@E:@GC<J F= C@E@:8C ,<J<8I:? <;@K<; 9P !@FM8EE8 ;@ #>E8Q@F
@ !@FM8EE8
8E; "8PE<J